Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 1378 record(s)

Req # A-2021-000073

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_03706888, E2B_03703577, E2B_03690817, E2B_03650148, E2B_03703572, 000934984, 000934900. ADRs for Vyvanse. Report numbers: 000933539, 000934356, 000934242, 000933957. ADR for Antihemophilic factor (recombinant). Report number: E2B_03664870. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_03673052, E2B_03667877, E2B_03698698. ADR for Gammagard Liquid. Report number: 000933632.

Organization: Health Canada

116 page(s)
December 2021

Req # A-2021-000177

Adverse Drug Reaction (ADR). Report number: E2B_03769938.

Organization: Health Canada

11 page(s)
December 2021

Req # A-2021-000187

Adverse Drug Reactions (ADRs). Report numbers: E2B_00767615, E2B_02625820, E2B_03239333, E2B_03294549, E2B_03344059, E2B_03353109, E2B_02247251, E2B_03317883, E2B_02625820, E2B_02676622.

Organization: Health Canada

466 page(s)
December 2021

Req # A-2021-000287

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-106381-329, Canada–Northwest Territories Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19.

Organization: Health Canada

23 page(s)
December 2021

Req # A-2021-000323

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-104716-552, Canada-Nova Scotia Bilateral Agreement for Pan-Canadian Virtual Care Priorities in Response to COVID-19.

Organization: Health Canada

35 page(s)
December 2021

Req # A-2021-000373

Adverse Drug Reaction (ADR). Report number: E2B_03829519.

Organization: Health Canada

10 page(s)
December 2021

Req # A-2021-000420

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075019-732.

Organization: Health Canada

6 page(s)
December 2021

Req # A-2021-000475

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-114293-165, Amendments to the Patented Medicines Regulations.

Organization: Health Canada

35 page(s)
December 2021

Req # A-2021-000479

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116936-246.

Organization: Health Canada

15 page(s)
December 2021

Req # A-2021-000506

Adverse Drug Reaction (ADR) TERIFLUNOMIDE. Report number: E2B_03519847.

Organization: Health Canada

8 page(s)
December 2021
Date modified: